Buffett says drugmaker Valeant had flawed business model


Save Story
Leer en español

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

OMAHA, Neb. (AP) — Investor Warren Buffett says Valeant Pharmaceuticals' practices were flawed, so he declined to invest Berkshire Hathaway's money in the company.

Buffett appeared on CNBC Monday after meeting with Berkshire Hathaway shareholders over the weekend.

Buffett says some Valeant shareholders urged him to look at investing in Valeant in recent years, but he decided not to after examining the company.

Valeant is dealing with intense scrutiny of its business practices, a huge drop in stock price and insurers are demanding discounts from its drug prices.

Current and former Valeant officials were grilled by Congress last week over the company's strategy of buying up older medicines with limited competition and then jacking up their prices many times above prior levels.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

Business
The Associated Press

    STAY IN THE KNOW

    Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast